These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 29133607

  • 1. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607
    [Abstract] [Full Text] [Related]

  • 2. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E.
    Circulation; 2021 Feb 23; 143(8):770-779. PubMed ID: 33302723
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
    Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N.
    Diabetes Obes Metab; 2018 Nov 23; 20(11):2585-2597. PubMed ID: 29938883
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH, Li YR, Chen SW, Lin YS, Sun CC, Chen DY, Mao CT, Wu M, Chang CH, Chu PH, Wu VC.
    Cardiovasc Diabetol; 2020 Nov 09; 19(1):189. PubMed ID: 33167990
    [Abstract] [Full Text] [Related]

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
    Lin YH, Lin CH, Lin YC, Huang YY, Tai AS, Fu SC, Lin SH.
    Endocr Pract; 2024 May 09; 30(5):424-430. PubMed ID: 38325629
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study.
    Udell JA, Yuan Z, Ryan P, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Endocrinol Diabetes Metab; 2020 Jan 09; 3(1):e00096. PubMed ID: 31922023
    [Abstract] [Full Text] [Related]

  • 7. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 8. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z.
    J Am Heart Assoc; 2021 Jun 30; 10(11):e020237. PubMed ID: 34013739
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M, Melzer-Cohen C, Rozenberg A, Yanuv I, Chodick G, Karasik A, Kosiborod M, Mosenzon O.
    Cardiovasc Diabetol; 2021 Aug 18; 20(1):169. PubMed ID: 34407822
    [Abstract] [Full Text] [Related]

  • 12. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group.
    Circulation; 2018 Jan 23; 137(4):323-334. PubMed ID: 29133604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H.
    Am J Med; 2020 Nov 23; 133(11):e625-e630. PubMed ID: 32389659
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Yen FS, Hwu CM, Liu JS, Wu YL, Chong K, Hsu CC.
    Ann Intern Med; 2024 Jun 23; 177(6):693-700. PubMed ID: 38684099
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.